Showing results (191-200 of 262) with videos related to
Sort By:
Pageof 27
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 8, 2016
Developments in targeted therapy in melanomaV C Amann, E Ramelyte, S Thurneysen, et al.British Journal of Cancer|May 29, 2008
The influence of sentinel lymph node tumour burden on additional lymph node involvement and disease-free survival in cutaneous melanoma--a retrospective analysis of 392 casesM Guggenheim, R Dummer, F J Jung, et al.BMC Cancer|April 16, 2020
Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effectJ Boegeholz, C S Brueggen, C Pauli, et al.Cancer|May 1, 1991
Formation of neutralizing antibodies against natural interferon-beta, but not against recombinant interferon-gamma during adjuvant therapy for high-risk malignant melanoma patientsR Dummer, W Müller, F Nestle, et al.Cancer Gene Therapy|August 5, 2000
Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumorsR Dummer, J Bergh, Y Karlsson, et al.The American Journal of Pathology|September 11, 2001
Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 productionM Urosevic, M O Kurrer, J Kamarashev, et al.The British Journal of Dermatology|March 26, 2003
Pyogenic lymphoma of the skin: a peculiar variant of primary cutaneous neutrophil-rich CD30+ anaplastic large-cell lymphoma. Clinicopathological study of four cases and review of the literatureG Burg, W Kempf, D V Kazakov, et al.The British Journal of Dermatology|August 29, 2012
Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056)S Whittaker, P Ortiz, R Dummer, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|November 24, 2018
The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanomaN P Graf, P Koelblinger, N Galliker, et al.Melanoma Research|April 1, 1997
D1 dopamine receptors are not expressed in human melanomaR Böni, W Lichtensteiger, H C Steinert, et al.Pageof 27